2-(4-氰基苯基)-1 3-二氧戊环 | 66739-89-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(4-氰基苯基)-1 3-二氧戊环
• 中文别名: 2-(4-氰基苯基)-13-二氧戊环
• 英文名称: 4-(1,3-dioxolan-2-yl)benzonitrile
• 英文别名: 4-(1,3-dioxacyclopent-2-yl)benzonitrile
• CAS: 66739-89-7
• 化学式: C₁₀H₉NO₂
• mdl: MFCD00052570
• 分子量: 175.187
• InChiKey: AQXQCWAXQJVTKU-UHFFFAOYSA-N

物化性质

• 熔点：
  39 °C(Solv: ethyl ether (60-29-7); pentane (109-66-0))
• 沸点：
  317.6±37.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  42.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  6.1
• 海关编码：
  2932999099
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P261,P264,P270,P271,P280,P302+P352,P304+P340,P310,P330,P361,P403+P233,P405,P501
• 危险品运输编号：
  3439
• 危险性描述：
  H301,H311,H331
• 储存条件：
  2-8℃

反应信息

• 作为反应物：
  描述：

  2-(4-氰基苯基)-1 3-二氧戊环 在 盐酸羟胺 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 19.0h， 生成 4-(1,3-dioxolan-2-yl)-N'-((ethoxycarbonyl)oxy)benzimidamide
  参考文献：
  名称：

  Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores

  摘要：

  Dual antithrombotic agents acting as anticoagulants and aggregation inhibitors could have substantial advantages over currently prescribed combinations of antithrombotic drugs. Herein, we report compounds with moderate inhibitory activity for factor Xa and fibrinogen GPIIb/IIIa binding (both in the micromolar range). These compounds resulted from our efforts to merge the pharmacophores of selective factor Xa inhibitor rivaroxaban with a mimic of the Arg-Gly-Asp (RGD) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity. Resulting from this study, a structurally novel class of submicromolar fibrinogen GPIIb/IIIa binding inhibitor bearing 1,2,4-oxadiazol-5(4H)-one moiety is also described. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.03.056
• 作为产物：
  描述：

  4-溴苯腈 在 异丙基氯化镁 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 乙醚 、 甲苯 为溶剂， 反应 22.33h， 生成 2-(4-氰基苯基)-1 3-二氧戊环
  参考文献：
  名称：

  Identification and Structure–Activity Relationship (SAR) of potent and selective oxadiazole-based agonists of sphingosine-1-phosphate receptor (S1P1)

  摘要：

  Agonism of S1P(1) receptor has been proven to be responsible for peripheral blood lymphopenia and elicts the identification of various S1P(1) modulators. In this paper we described a series of oxadiazole-based S1P(1) direct-acting agonists disubstituted on terminal benzene ring, with high potency for S1P(1) receptor and favorable selectivity against S1P(3) receptor. In addition, two representative agents named 16-3b and 16-3g demonstrated impressive efficacy in lymphocyte reduction along with reduced effect on heart rate when orally administered. Furthermore, these compounds have been shown to possess desired pharmacokinetic (PK) and physicochemical profiles. The binding mode between 16-3b and the activated S1P(1) model was also studied.

  DOI：

  10.1016/j.bioorg.2018.09.008

文献信息

• Transformation of aromatic bromides into aromatic nitriles with n-BuLi, pivalonitrile, and iodine under metal cyanide-free conditions
  作者：Ko Uchida、Hideo Togo

  DOI：10.1016/j.tet.2019.130550

  日期：2019.9

  by the treatment of aryl bromides with n-butyllithium and then pivalonitrile, followed by the treatment with molecular iodine at 70 °C, without metal cyanides under transition-metal-free conditions. The present reaction proceeds through the radical β-elimination of imino-nitrogen-centered radicals formed from the reactions of imines and N-iodoimines under warming conditions. © 2019 Elsevier Science

  通过先用正丁基锂然后再用新戊腈处理芳基溴化物，然后在无过渡金属的条件下用分子碘在70°C的温度下处理（不使用金属氰化物），可以以高收率获得各种芳族腈。本反应通过在加热条件下由亚胺和N-碘亚胺的反应形成的以亚氨基氮为中心的自由基的β-消除进行。分级为4 +©2019 Elsevier Science。版权所有。
• 含二苯基噁二唑的羧酸类化合物、其制备方法 及医药用途
  申请人：中国医学科学院药物研究所

  公开号：CN109956912B

  公开（公告）日：2021-10-22

  本发明涉及药物化学领域，具体涉及一类含二苯基噁二唑骨架的羧酸类化合物(I)，其制备方法，药物制剂，及其作为药物，尤其作为免疫调节药物的用途。药理试验证明，本发明的羧酸类化合物对鞘胺醇‑1‑磷酸受体1(S1P1)具有较强的激动活性，该类化合物可用于制备一系列治疗自身免疫性疾病，如多发硬化症、类风湿关节炎、系统性红斑狼疮、牛皮癖、银屑病等，并可用于减轻器官移植排异反应。
• [EN] NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] NOUVELLES MÉTHODES DE TRAITEMENT DES MALADIES INFLAMMATOIRES
  申请人：CORTICAL PTY LTD

  公开号：WO2004089927A1

  公开（公告）日：2004-10-21

  Methods of inhibiting the cytokine or biological activity of Macrophage Migration Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) are provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of compounds of formula (I), either alone or as a part of combination therapy. Novel compounds of formula (I) are also provided for.

  提供了抑制巨噬细胞迁移抑制因子（MIF）细胞因子或生物活性的方法，包括将MIF与式（I）化合物接触。该发明还涉及治疗MIF细胞因子或生物活性参与的疾病或病况的方法，包括给予式（I）化合物的治疗，可以单独使用或作为联合疗法的一部分。还提供了式（I）的新化合物。
• BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE
  申请人：National Health Research Institutes

  公开号：US20200071312A1

  公开（公告）日：2020-03-05

  Benzimidazole compounds of formula (I), shown below, are disclosed. The compounds are potent human glutaminyl cyclase inhibitors. Also disclosed is a pharmaceutical composition containing one of these compounds and a pharmaceutical acceptable carrier, as well as a method of treating Alzheimer's disease or Huntington's disease by administering to a subject in need thereof an effective amount of such a compound.

  以下显示的化学式（I）的苯并咪唑化合物已被披露。这些化合物是强效的人类谷氨酰环化酶抑制剂。还披露了一种含有其中一种这些化合物和一种药用可接受载体的药物组合物，以及通过向需要的受试者施用这种化合物的有效量来治疗阿尔茨海默病或亨廷顿病的方法。
• Ni-catalyzed reductive decyanation of nitriles with ethanol as the reductant
  作者：Ke Wu、Yichen Ling、Nan Sun、Baoxiang Hu、Zhenlu Shen、Liqun Jin、Xinquan Hu

  DOI：10.1039/d0cc07743g

  日期：——

  A nickel-catalyzed reductive decyanation of aromatic nitriles has been developed, in which the readily available and abundant ethanol was applied as the hydride donor. Various functional groups on the aromatic rings, such as alkoxyl, amino, imino and amide, were compatible in this catalytic protocol. Heteroaryl, benzylic and alkenyl nitriles were also tolerated. Mechanistic investigation indicated

  已经开发出镍催化的芳香腈的还原性脱氰，其中易得且丰富的乙醇用作氢化物供体。在该催化方案中，芳环上的各种官能团如烷氧基，氨基，亚氨基和酰胺是相容的。杂芳基，苄基和烯基腈也可耐受。机理研究表明，在该还原性脱氰反应中，乙醇通过消除β-氢化物有效地提供了氢化物。